Life Science Giant Danaher's Q2 Earnings Beat Estimates On 'Sustained Positive Momentum In Bioprocessing Business', Maintains Guidance
Life Science Giant Danaher's Q2 Earnings Beat Estimates On 'Sustained Positive Momentum In Bioprocessing Business', Maintains Guidance
On Tuesday, Danaher Corp's (NYSE:DHR) second quarter sales decreased 3% year-over-year to $$5.743 billion, beating the consensus of $5.59 billion.
丹纳赫公司（NYSE:DHR）今年第二季度销售额同比下降3%，为$5.743亿，超过了$5.59亿的共识。
Non-GAAP core revenue decreased by 3.5%, compared to the expectations of a decline in the mid-single digits.
非通用会计原则核心营收下降了3.5%，预计将下降中单数位。
Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57.
丹纳赫报告第二季度调整后每股收益为$1.72，超过了$1.57的共识。
Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.
经营现金流为14亿美元，非通用会计原则下的自由现金流为11亿美元。
Rainer M. Blair, President and Chief Executive Officer, stated, "We were particularly pleased with the sustained positive momentum in our bioprocessing business and with strong performance at Cepheid, which we believe gained market share in molecular testing again this quarter."
总裁兼首席执行官雷内·M·布莱尔表示：“我们特别满意于生物加工业务持续的正向动力以及赛福特表现强劲，我们相信在本季度分子检测领域取得了市场份额。”
Also Read: Danaher's Spun-Off Company Veralto Is "Next High-Quality Serial Compounder" – Analyst.
也阅读：丹纳赫的分拆公司Veralto被分析师誉为“下一个高质量的连续化合物”
Biotechnology sales fell 9% from $1.86 billion to $1.71 billion. Life Sciences segment sales decreased slightly from $1.79 billion to $1.77 billion. Diagnostic sales increased from $2.23 billion to $2.26 billion.
生物技术销售额从18.6亿美元下降9%至17.1亿美元。生命科学业务销售额从17.9亿美元略微下降至17.7亿美元。诊断销售额从22.3亿美元上升至22.6亿美元。
The operating margin of 27.3% came in above the guidance of around 26%.
营业利润率为27.3%，高于约26%的指导。
Guidance: Danaher expects the fiscal year 2024 non-GAAP core revenue to be down low-single digits year-over-year.
丹纳赫预计2024财年非通用会计原则核心收入将同比下降个位数。
For the third quarter of 2024, Danaher anticipates non-GAAP core revenue will be down in the low-single digits year-over-year.
对于2024财年第三季度，丹纳赫预计非通用会计原则核心营收将同比下降个位数。
The company forecasts a third-quarter adjusted operating margin of around 26% and reaffirms fiscal year 2024 margin guidance of ~29%.
公司预测第三财季调整后营业利润率约为26%，并重申2024财年利润率指导约为29%。
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around $1.6 billion.
公司预测2024生物加工核心收入将单位数下降，而赛福特2024呼吸道收入将约为16亿美元。
Price Action: At the last check on Tuesday, DHR stock was up 7.20% at $268.96.
价格行动：在周二的最后一次检查中，DHR股票上涨7.20%，至268.96美元。
- EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder.
- Adial Pharmaceuticals独家报道：AD04用于酒精性障碍的药物代谢动力学研究进入第二队。
Photo via Company
照片来自公司